v3 Template
A

AeroRx Therapeutics

Biopharmaceutical ~120 employees
Founded
--
Employees (Est.)
~120
8 leaders known
Total Funding
$21.0M
Funding Rounds
1
Last Funding
2025-10-07

About AeroRx Therapeutics

AeroRx Therapeutics is a clinical-stage biopharmaceutical company focused on developing best-in-class nebulized combination therapies for moderate-to-severe COPD patients, addressing treatment gaps for those underserved by traditional inhalers.

Products & Services

Aero 007:A nebulized LABA/LAMA combination therapy for respiratory (COPD) treatment, currently in Phase 2 clinical development.

Specialties

Nebulized therapies for COPD Combination treatments (LABA/LAMA, LABA/LAMA/ICS) Respiratory drug delivery

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series A
T: -
FT: Series A 		A: 21000000
MR: -
FA: $21 million
FAN: 21000000 		D: 2025-10-07
FD: 2025-10-07 		3 investors
Series A Latest
2025-10-07
$21.0M
3 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

A

Ahmet Tutuncu, MD, PhD

CEO and Co-founder

LinkedIn (Pro only)
J

John Lord

Pharmaceutical Development

P

Paul Laskar

Pharmaceutical Development

M

Mei-chang Kuo

Pharmaceutical Development

P

Peter Fernandes

Regulatory & QA

N

Nani Kadrichu

Aerosol Science/Drug Delivery

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

AeroRx Therapeutics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceutical
Company Size
~120 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro